229 related articles for article (PubMed ID: 24352914)
1. Anxiety, attention problems, hyperactivity, and the Aberrant Behavior Checklist in fragile X syndrome.
Wheeler A; Raspa M; Bann C; Bishop E; Hessl D; Sacco P; Bailey DB
Am J Med Genet A; 2014 Jan; 164A(1):141-55. PubMed ID: 24352914
[TBL] [Abstract][Full Text] [Related]
2. Validity of a condition specific outcome measure for fragile X syndrome: the Aberrant Behaviour Checklist-utility index.
Raspa M; Sacco P; Candrilli SD; Bishop E; Petrillo J
J Intellect Disabil Res; 2016 Sep; 60(9):844-55. PubMed ID: 26929037
[TBL] [Abstract][Full Text] [Related]
3. Health and economic consequences of fragile X syndrome for caregivers.
Bailey DB; Raspa M; Bishop E; Mitra D; Martin S; Wheeler A; Sacco P
J Dev Behav Pediatr; 2012; 33(9):705-12. PubMed ID: 23117595
[TBL] [Abstract][Full Text] [Related]
4. Medication utilization for targeted symptoms in children and adults with fragile X syndrome: US survey.
Bailey DB; Raspa M; Bishop E; Olmsted M; Mallya UG; Berry-Kravis E
J Dev Behav Pediatr; 2012 Jan; 33(1):62-9. PubMed ID: 22064563
[TBL] [Abstract][Full Text] [Related]
5. Factor Structure of the Aberrant Behavior Checklist in Individuals with Fragile X Syndrome: Clarifications and Future Guidance.
Aman MG; Norris M; Kaat AJ; Andrews H; Choo TH; Chen C; Wheeler A; Bann C; Erickson C
J Child Adolesc Psychopharmacol; 2020 Oct; 30(8):512-521. PubMed ID: 32746626
[No Abstract] [Full Text] [Related]
6. Characterization, treatment patterns, and patient-related outcomes of patients with Fragile X syndrome in Germany: final results of the observational EXPLAIN-FXS study.
Haessler F; Gaese F; Huss M; Kretschmar C; Brinkman M; Peters H; Elstner S; Colla M; Pittrow D
BMC Psychiatry; 2016 Sep; 16(1):318. PubMed ID: 27612457
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal trajectories of aberrant behavior in fragile X syndrome.
Hustyi KM; Hall SS; Jo B; Lightbody AA; Reiss AL
Res Dev Disabil; 2014 Nov; 35(11):2691-701. PubMed ID: 25129200
[TBL] [Abstract][Full Text] [Related]
8. Psychometric study of the Aberrant Behavior Checklist in Fragile X Syndrome and implications for targeted treatment.
Sansone SM; Widaman KF; Hall SS; Reiss AL; Lightbody A; Kaufmann WE; Berry-Kravis E; Lachiewicz A; Brown EC; Hessl D
J Autism Dev Disord; 2012 Jul; 42(7):1377-92. PubMed ID: 21972117
[TBL] [Abstract][Full Text] [Related]
9. Autism and anxiety in males with fragile X syndrome: an exploratory analysis of neurobehavioral profiles from a parent survey.
Talisa VB; Boyle L; Crafa D; Kaufmann WE
Am J Med Genet A; 2014 May; 164A(5):1198-203. PubMed ID: 24664669
[TBL] [Abstract][Full Text] [Related]
10. The aberrant behavior profile in Indonesian individuals with fragile X syndrome with limited genetic services.
Winarni TI; Sumekar TA; Sarjana W; Hardian H; Hagerman RJ; Faradz SM
Intractable Rare Dis Res; 2022 Nov; 11(4):215-218. PubMed ID: 36457587
[TBL] [Abstract][Full Text] [Related]
11. A comparison of family financial and employment impacts of fragile X syndrome, autism spectrum disorders, and intellectual disability.
Ouyang L; Grosse SD; Riley C; Bolen J; Bishop E; Raspa M; Bailey DB
Res Dev Disabil; 2014 Jul; 35(7):1518-27. PubMed ID: 24755230
[TBL] [Abstract][Full Text] [Related]
12. Telehealth-enabled behavioral treatment for problem behaviors in boys with fragile X syndrome: a randomized controlled trial.
Hall SS; Monlux KD; Rodriguez AB; Jo B; Pollard JS
J Neurodev Disord; 2020 Nov; 12(1):31. PubMed ID: 33218305
[TBL] [Abstract][Full Text] [Related]
13. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.
Heussler H; Cohen J; Silove N; Tich N; Bonn-Miller MO; Du W; O'Neill C; Sebree T
J Neurodev Disord; 2019 Aug; 11(1):16. PubMed ID: 31370779
[TBL] [Abstract][Full Text] [Related]
14. Elimination disorders in persons with Prader-Willi and Fragile-X syndromes.
Equit M; Piro-Hussong A; Niemczyk J; Curfs L; von Gontard A
Neurourol Urodyn; 2013 Sep; 32(7):986-92. PubMed ID: 23239431
[TBL] [Abstract][Full Text] [Related]
15. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome.
Berry-Kravis E; Sumis A; Hervey C; Nelson M; Porges SW; Weng N; Weiler IJ; Greenough WT
J Dev Behav Pediatr; 2008 Aug; 29(4):293-302. PubMed ID: 18698192
[TBL] [Abstract][Full Text] [Related]
16. Early temperament and negative reactivity in boys with fragile X syndrome.
Shanahan M; Roberts J; Hatton D; Reznick J; Goldsmith H
J Intellect Disabil Res; 2008 Oct; 52(10):842-54. PubMed ID: 18498331
[TBL] [Abstract][Full Text] [Related]
17. [Can the behavioural phenotype of fragile X syndrome be attributed to mental retardation and to attention deficit hyperactivity disorder?].
Artigas-Pallarés J; Brun-Gasca C
Rev Neurol; 2004 Jan 1-15; 38(1):7-11. PubMed ID: 14730483
[TBL] [Abstract][Full Text] [Related]
18. Anxiety and threat-related attentional biases in adolescents with fragile X syndrome.
Kelleher BL; Hogan AL; Ezell J; Caravella K; Schmidt J; Wang Q; Roberts JE
J Intellect Disabil Res; 2020 Apr; 64(4):296-302. PubMed ID: 32020687
[TBL] [Abstract][Full Text] [Related]
19. Open-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello C; Tao L; Folino A; Berry-Kravis E; Tranfaglia M; Ethell IM; Ethell DW
BMC Neurol; 2010 Oct; 10():91. PubMed ID: 20937127
[TBL] [Abstract][Full Text] [Related]
20. Observable Symptoms of Anxiety in Individuals with Fragile X Syndrome: Parent and Caregiver Perspectives.
Lozano R; Thompson T; Dixon-Weber J; Erickson CA; Berry-Kravis E; Williams S; Smith E; Frazier JA; Rosselot H; Farmer C; Hessl D
Genes (Basel); 2022 Sep; 13(9):. PubMed ID: 36140827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
